Spruce Biosciences, Inc.
SPRB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001683553
No open-market purchases or sales by Spruce Biosciences, Inc. insiders were filed in the last 90 days; 65 institutions reported holding it in 13F filings for Q2 2026, worth $116.3M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +33 vs. previous quarter
- 65
- 13F valueReported value at the end of Q2 2026
- $116.3M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding SPRB, Q2 2026
No superinvestor reported holding SPRB at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Spruce Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 15, 2025 (view filing)4:32 PM ET | Oct 6 | 9 daysLate | Parkman Healthcare Partners LLC and 1 other10% Owner | PPurchaseCommon Stock, $0.001 par value per share | +256 | $17.91 | +$4.59K | +24.4%1.31K after | |
| Oct 15, 2025 (view filing)4:32 PM ET | Oct 6 | 9 daysLate | Parkman Healthcare Partners LLC and 1 other10% Owner | SSaleCommon Stock, $0.001 par value per share | −257 | $19.14 | −$4.92K | −19.7%1.05K after | 2 lots |
| Oct 8, 2025 (view filing) | Oct 6 | 2 days | Parkman Healthcare Partners LLC10% Owner | PPurchaseCommon Stock, $0.001 par value per share | +256 | $17.91 | +$4.58K | +24.4%1.31K after | |
| Oct 8, 2025 (view filing) | Oct 6 | 2 days | Parkman Healthcare Partners LLC10% Owner | SSaleCommon Stock, $0.001 par value per share | −257 | $19.15 | −$4.92K | −19.7%1.05K after | 2 lots |
| Mar 25, 2024 (view filing) | Mar 21 | 4 days | Novo Holdings A/S10% Owner | SSale | −465.0K | $0.75 | −$348.8K | −15.4%2.55M after | |
| Mar 20, 2024 (view filing) | Mar 18-20 | 2 days | Novo Holdings A/S10% Owner | SSale | −1.79M | $0.7587 | −$1.36M | −37.3%3.02M after | 3 lots |
| Mar 18, 2024 (view filing) | Mar 14 | 4 days | Novo Holdings A/S10% Owner | SSale | −1.91M | $0.89 | −$1.70M | −28.4%4.81M after | |
| May 16, 2023 (view filing) | Feb 16 | 89 daysLate | O'Donnell NiallDirector | PPurchase | +630.4K | $3.17 | +$2.00M | +90.6%1.33M after | |
| May 16, 2023 (view filing) | Feb 16 | 89 daysLate | O'Donnell NiallDirector | PPurchase | +472.8K | – | – | –472.8K after | Derivative |
| Feb 21, 2023 (view filing) | Feb 16 | 5 days | Novo Holdings A/S10% Owner | PPurchase | +2.21M | $3.17 | +$7.00M | +48.9%6.72M after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Spruce Biosciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| AIGH Capital Management LLC | 250,000 | $13.5M | 1.22% | +250,000 | New |
| OrbiMed Advisors LLC | 200,000 | $10.8M | 0.20% | +200,000 | New |
| BlackRock, Inc. | 187,836 | $10.1M | 0.00% | +170,898+1,009.0% | Added |
| Millennium Management LLC | 160,981 | $8.69M | 0.01% | +49,093+43.9% | Added |
| AWM Investment Company, Inc. | 146,988 | $7.94M | 0.69% | +146,988 | New |
| Ikarian Capital, LLC | 121,356 | $6.55M | 1.07% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 119,331 | $6.44M | 0.00% | +100,994+550.8% | Added |
| Alyeska Investment Group, L.P. | 81,671 | $4.41M | 0.01% | +30,000+58.1% | Added |
| Geode Capital Management, LLC | 70,548 | $3.81M | 0.00% | +57,659+447.4% | Added |
| ADAR1 Capital Management, LLC | 67,717 | $3.66M | 0.17% | +9,117+15.6% | Added |